The study points out that this probably means that Travellan has a GREATER effect on the more dangerous pathogens, so would be an advantatge not a disadvantage. I've cut out the comment below but of course form your own opinion. My overarching comment re this stock has always been that it is way undervalued seeing it has so much cash in the bank and is already generating revenue from sales. I'm not going to argue semantics on just how good the product is.
Studies using the CHIM for a variety of different enteric pathogens suggest the greatest protection may be againstmore severe disease and in studies where the disease appears to be predominately mild, which appears to be the casein this study, the efficacy estimates can be lower than anticipated.
- Forums
- ASX - By Stock
- IMC
- Ann: Travelan to progress to Phase 3 Clinical Trials in the US
Ann: Travelan to progress to Phase 3 Clinical Trials in the US, page-92
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMC (ASX) to my watchlist
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.93M |
Open | High | Low | Value | Volume |
11.0¢ | 11.0¢ | 10.5¢ | $13.47K | 123.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 12766 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 257145 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12766 | 0.105 |
5 | 347605 | 0.100 |
1 | 52520 | 0.095 |
1 | 9695 | 0.092 |
2 | 145000 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 117145 | 4 |
0.115 | 100000 | 2 |
0.120 | 193000 | 3 |
0.130 | 218736 | 6 |
0.140 | 105750 | 2 |
Last trade - 14.32pm 26/08/2024 (20 minute delay) ? |
Featured News
IMC (ASX) Chart |